Tumor length as a prognostic factor in esophageal cancer management
Conclusion
The increased risk of mortality associated with longer tumors, with the effect largely influenced by the stage I patients, helps generate a hypothesis that tumor length may have greater prognostic significance in stage I patients than in stage II/III patients. Our findings suggest that it may be helpful to include tumor length in esophageal cancer staging guidelines. (Source: Journal of Radiation Oncology)
Source: Journal of Radiation Oncology - January 28, 2015 Category: Cancer & Oncology Source Type: research
Hypofractionated intensity-modulated radiation therapy for prostate cancer confined to the pelvis: analysis of efficacy and late toxicity
Conclusion
Moderately hypofractionated IMRT for prostate cancer is efficacious and well-tolerated in this predominantly high-risk, locally advanced, or N1 Chinese patients and is associated with low rates of severe late toxicity during early follow-up. (Source: Journal of Radiation Oncology)
Source: Journal of Radiation Oncology - January 16, 2015 Category: Cancer & Oncology Source Type: research
Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER
Discussion
RT usage has changed significantly over the past four decades, particularly in disease sites with highest incidence, such as lung, breast and prostate cancer. As radiation oncology evolves in its technology and applications, knowledge of the changes in clinical use will be important in identifying and investing in the needed RT health resources for the future. (Source: Journal of Radiation Oncology)
Source: Journal of Radiation Oncology - January 16, 2015 Category: Cancer & Oncology Source Type: research
Hypofractionated radiotherapy with concurrent temozolomide chemotherapy in patients with newly diagnosed RPA class V glioblastoma multiforme: promising early results
Conclusion
The HFRT/TMZ regimen was safe, well tolerated, and convenient for GBM patients with the poorest prognosis, rendering a shorter overall treatment time and no increase in toxicity. (Source: Journal of Radiation Oncology)
Source: Journal of Radiation Oncology - January 7, 2015 Category: Cancer & Oncology Source Type: research
The use of modern imaging technologies in radiation therapy of cervical cancer
Abstract
Over the past century, definitive management of unresectable cervical cancer has evolved and currently employs high-dose radiation treatment with teletherapy and intracavitary brachytherapy (ICBT) components, combined with concurrent chemotherapy. Reflecting high disease prevalence among developing nations, the International Federation of Gynecology and Obstetrics (FIGO) staging of cervical cancer relies on clinical assessment, with limited radiographic studies. However, multiple clinicopathologic analyses describe suboptimal correlation between clinical examination findings and pathologic stage....
Source: Journal of Radiation Oncology - January 5, 2015 Category: Cancer & Oncology Source Type: research
Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses
Conclusion
Patients with recurrent lung cancer have limited options. SBRT re-irradiation is tolerable even after a median 61.2 Gy to the re-irradiation site. The lower BED used provided acceptable progression-free survival with low toxicity. Given the poor prognosis with current treatment options, new paradigms for re-treatment should include SBRT-re-irradiation as an adjunct to systemic therapy for in-field lung cancer recurrence. (Source: Journal of Radiation Oncology)
Source: Journal of Radiation Oncology - December 10, 2014 Category: Cancer & Oncology Source Type: research
[ 11 C]-Choline PET/CT-guided simultaneous integrated boost to dominant intraprostatic lesions using intensity-modulated radiation therapy with helical tomotherapy technique for dose escalation
Conclusion
It is feasible in selected patients to use [11C]-choline PET/CT to deliver hypofractionated dose-escalated helical tomotherapy to dominant intraprostatic lesions with simultaneous integrated boost using clinically established normal tissue constraints. (Source: Journal of Radiation Oncology)
Source: Journal of Radiation Oncology - December 6, 2014 Category: Cancer & Oncology Source Type: research
Treatment of maxillary sinus cancer in the modern era: one institution’s experience
Conclusion
Treatment outcomes for maxillary sinus cancer remain poor, although a combined therapeutic approach continues to provide the best survival and local recurrence outcomes. This suggests the need for further treatment escalation. (Source: Journal of Radiation Oncology)
Source: Journal of Radiation Oncology - November 23, 2014 Category: Cancer & Oncology Source Type: research
